Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant treatment with atezolizumab or placebo and trastuzumab emtansine in HER2+-positive breast cancer at high risk of recurrence of
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ROCHE FARMA, SA
- Phase: III
- Execution start: 25/01/2021
- End of execution: 31/12/2031
- IP: ISABEL BLANCAS LOPEZ-BARAJAS